中国经济网北京2月11日讯 日前，中国裁判文书网公布的一则二审民事判决书，揭开了中国光大银行（601818）违规代销信托产品的隐秘一角。一位投资者 斥资300万元认购该行推介的煤炭产业信托，最终仅收回本金163.87万余元，亏损幅度超45%、金额高达136万余元。 通过案号的对比，可以发现涉案银行为中国光大银行，涉案信托产品为"长安信托·煤炭资源产业投资基金3号"。法院终审判决认定，作为代销机构的光大银 行存在违规销售行为，需承担20%的损失赔偿责任，即赔付投资者近27.3万元。 上海金融法院民事判决书【（2025）沪74民终1080号】显示，耿某在某银行市东支行处经某银行市东支行工作人员推荐，认购《某信托·煤炭资源产业投资 基金3号集合资金信托计划》，签署《某信托·煤炭资源产业投资基金3号集合资金信托计划认购风险申明书》。同日，耿某向某国际信托公司汇款300万元， 附言："耿某认购长安楼俊项目"。某国际信托公司合计向耿某分配信托收益285,000元，分配信托本金1,637,429.14元。 2015年10月27日，中国银行业监督管理委员会上海监管局出具银监发〔2015〕169号《上海银监局关于某银行上海分行 ...

Core Viewpoint - The announcement details the overdue payment situation regarding the "Guomin Trust · Huijin No. 87 Collective Fund Trust Plan," highlighting the company's receipt of a principal amount of 169.99 million yuan and the ongoing efforts to manage the associated loan rights and collateral assets [1][4]. Summary by Sections Situation Overview - The company approved the use of up to 600 million yuan of idle funds for cash management, specifically for purchasing financial products from banks and trust companies, with a maximum investment of 170 million yuan in the "Guomin Trust · Huijin No. 87 Collective Fund Trust Plan" [1]. - The trust plan was established with a total scale of 200 million yuan, with the company contributing 170 million yuan, and as of the maturity date, only 10,000 yuan had been repaid, leaving an outstanding balance of 199.99 million yuan [1]. Progress of Trust Product Purchase - The company, as the trustee, has been actively pursuing the transfer of loan rights related to the trust plan to its subsidiary, Zhizhu Space (Tianjin) Technology Co., Ltd., which has signed a debt transfer agreement with Guomin Trust [2][3]. Subsequent Disposal Work Progress and Plans - Zhizhu Space is tasked with managing the loan rights and collateral assets, including applying to change the executor in a court case and potentially auctioning off collateral properties [4]. - The company emphasizes the importance of effective governance and risk control in overseeing Zhizhu Space's operations and financial management [4]. Impact on the Company - The company recognized a fair value change loss of 17 million yuan in 2022 and 68 million yuan in 2023 due to the trust product, which resulted in a net profit increase of 72.25 million yuan at the parent company level, although the consolidated net profit remains unchanged [5].

Core Viewpoint - The company received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, focusing on trust investments and equity investments, and has provided detailed responses to the inquiries [1][2]. Trust Investment - The company established a trust with Chang'an Trust, with a maximum trust fund of 400 million yuan, and the financing scale is 150 million yuan with a financing term of 24 months and a repurchase premium rate of 5% [1][2]. - The first phase of the trust investment amounted to 150 million yuan, corresponding to accounts receivable rights valued at 332.3028 million yuan [2][7]. - The underlying assets of the trust investment are accounts receivable rights from financing leases, and the exit method involves the financing party repurchasing the accounts receivable rights after 24 months [6][8]. - The company conducted due diligence on the financing party, but the internal control audit report indicated that the due diligence was not comprehensive, leading to a self-inspection and rectification process [1][10]. Equity Investment - The company invested 219 million yuan in Jiangsu Gairui, acquiring an 8.69% stake, with the investment funds specifically allocated for overseas digital medical business operations [14][22]. - Jiangsu Gairui reported total assets of 926.389 million yuan and net assets of 557.466 million yuan in 2024, with a net profit of 114.4543 million yuan [16][24]. - The investment aims to enhance shareholder returns and improve the efficiency of fund utilization, especially in light of declining revenues in the traditional retail sector [22][23]. - The company has no other business dealings with Jiangsu Gairui, and the investment funds did not flow to the company's actual controller or related parties [22][24].

Core Viewpoint - Hubei Junyao Health Beverage Co., Ltd. responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing concerns about trading financial assets, other receivables, and subsidiary equity acquisitions [1] Group 1: Trading Financial Assets - Junyao Health reported a year-end balance of trading financial assets of 155 million yuan, an increase of 84.27% year-on-year, with trust financial products accounting for 134 million yuan [2] - The trust plan "Aijian Win-Win - Shanghai Huade Accounts Receivable Debt Collection Fund Trust Plan" was established on July 28, 2023, with a term of 36 months and a maximum scale of 370 million yuan, raising 305.2 million yuan, with Junyao Health subscribing 130 million yuan at an annualized benchmark interest rate of 7.1% [2] Group 2: Other Receivables - The balance of other receivables at the end of the reporting period was 124 million yuan, with a bad debt provision of 16.16 million yuan [4] - The significant other receivables primarily stemmed from a partnership with Shengjiao Winery, which ended in December 2022, where Junyao Health is owed unconsumed prepayments [4] Group 3: Supply Chain Business - Junyao Health's supply chain business recognized sales revenue of 582 million yuan in 2024, down from 809 million yuan in the previous year [6] - The company engaged in transactions with Yihe (Shanghai) Supply Chain Management Co., Ltd., with procurement and sales amounts showing a downward trend [7] Group 4: Subsidiary Equity Acquisitions - During the reporting period, Junyao Health's subsidiary Meiri Boshi acquired three e-commerce companies, with the first two being established only 20 days prior to the acquisition [8] - The acquisitions aimed to quickly enter the online market and utilize existing e-commerce store qualifications to bypass platform review cycles, with the acquisitions being zero-cost [8]